Evofem Biosciences Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evofem Biosciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Evofem Biosciences stock.
View analyst ratings for Evofem Biosciences or view top-rated stocks.

Wall Street analysts have given Evofem Biosciences a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Evofem Biosciences wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Evofem Biosciences is scheduled to release its next quarterly earnings announcement on Wednesday, May 5th 2021.
View our earnings forecast for Evofem Biosciences.

Evofem Biosciences, Inc. (NASDAQ:EVFM) released its quarterly earnings results on Wednesday, March, 3rd. The biotechnology company reported ($0.50) EPS for the quarter, missing the consensus estimate of ($0.36) by $0.14. The biotechnology company had revenue of $0.17 million for the quarter, compared to analyst estimates of $1.70 million.
View Evofem Biosciences' earnings history.

Evofem Biosciences' stock was trading at $5.16 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, EVFM shares have decreased by 67.4% and is now trading at $1.68.
View which stocks have been most impacted by COVID-19.

7 Wall Street analysts have issued 12 month target prices for Evofem Biosciences' shares. Their forecasts range from $3.00 to $25.00. On average, they expect Evofem Biosciences' stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 495.2% from the stock's current price.
View analysts' price targets for Evofem Biosciences or view top-rated stocks among Wall Street analysts.

Some companies that are related to Evofem Biosciences include Evolus (EOLS), Inventiva (IVA), Aldeyra Therapeutics (ALDX), Mirum Pharmaceuticals (MIRM), AnaptysBio (ANAB), Eagle Pharmaceuticals (EGRX), SIGA Technologies (SIGA), Basilea Pharmaceutica (BPMUF), Urovant Sciences (UROV), Rigel Pharmaceuticals (RIGL), Provention Bio (PRVB), Fortress Biotech (FBIO), TherapeuticsMD (TXMD), Neoleukin Therapeutics (NLTX) and IVERIC bio (ISEE).
View all of EVFM's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Evofem Biosciences investors own include Matinas BioPharma (MTNB), ADMA Biologics (ADMA), Sorrento Therapeutics (SRNE), Bionano Genomics (BNGO), Zosano Pharma (ZSAN), Aeterna Zentaris (AEZS), OrganiGram (OGI), Gran Tierra Energy (GTE), Novan (NOVN) and KushCo (KSHB).

Evofem Biosciences trades on the NASDAQ under the ticker symbol "EVFM."

Evofem Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Valeo Financial Advisors LLC (0.03%). Company insiders that own Evofem Biosciences stock include Justin J File, Kelly Culwell, Kim P Kamdar, Lisa Dale Rarick, Ltd Invesco, Pdl Biopharma, Inc, Russell Barrans, Saundra L Pelletier and William Walmsley Hall.
View institutional ownership trends for Evofem Biosciences.

EVFM stock was sold by a variety of institutional investors in the last quarter, including Valeo Financial Advisors LLC. Company insiders that have sold Evofem Biosciences company stock in the last year include Kelly Culwell, Ltd Invesco, and Saundra L Pelletier.
View insider buying and selling activity for Evofem Biosciences or view top insider-selling stocks.

Shares of EVFM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of EVFM stock can currently be purchased for approximately $1.68.

Evofem Biosciences has a market capitalization of $139.65 million. The biotechnology company earns $-80,030,000.00 in net income (profit) each year or ($1.31) on an earnings per share basis.

Evofem Biosciences employs 147 workers across the globe.

The official website for Evofem Biosciences is www.evofem.com.

Evofem Biosciences is headquartered at 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130.

Evofem Biosciences' mailing address is 12400 HIGH BLUFF DRIVE SUITE 600, SAN DIEGO CA, 92130. The biotechnology company can be reached via phone at 858-550-1900 or via email at [email protected]